Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma | Zendy

Thomas Ollila | Zendy; Habibe Kurt | Zendy; Jozal Waroich | Zendy; John Vatkevich | Zendy; Ashlee Sturtevant | Zendy; Nimesh R. Patel | Zendy; Patrycja M. Dubielecka | Zendy; Diana O. Treaba | Zendy; Adam J. Olszewski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Author(s) -

Thomas Ollila,

Habibe Kurt,

Jozal Waroich,

John Vatkevich,

Ashlee Sturtevant,

Nimesh R. Patel,

Patrycja M. Dubielecka,

Diana O. Treaba,

Adam J. Olszewski

Publication year - 2020

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2020007236

Subject(s) - lymphoma , central nervous system , diffuse large b cell lymphoma , primary central nervous system lymphoma , medicine , pathology , oncology , biology

Ollila et al address a challenging problem: can the risk for central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma be predicted better on a molecular basis? They report that most tumors with CNS recurrence have recognizable molecular features that fall into two categories: those that resemble primary CNS lymphoma and those that resemble high-grade lymphoma. These data suggest that it is time to revisit identification of patients who may benefit from CNS prophylaxis, while highlighting how challenging that is.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research